Sunovion Pharmaceuticals Inc. to Present Three Posters on Results of One-year Large Simple Safety Study for BROVANA® (arformoterol tartrate) Inhalation Solution at 2013 American Thoracic Society International Conference
5/16/2013 10:05:52 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the company will present six posters at the 2013 American Thoracic Society (ATS) International Conference, three of which pertain to a recently completed, one-year, placebo-controlled, large simple safety study (LSSS) for BROVANA® (arformoterol tartrate) Inhalation Solution. BROVANA is a twice-daily nebulized long-acting beta2 agonist (LABA) that treats bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. The ATS conference is being held in Philadelphia on May 17-22, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by